To the Editor: Boyer et al. do not mention Behçet's disease among the possible causes of pulmonary hemorrhage. Pulmonary vascular problems, either pulmonary-artery aneurysms or involvement of the small vessels, are the main pulmonary disorders in Behçet's disease. Immunopathological findings indicate that the underlying 1.
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pathogenesis is pulmonary vasculitis, which may result in thrombosis, aneurysms, infarction, and hemorrhage. 1 Moreover, the patient described in the case report was found on esophagoscopy to have a proximal esophageal ulcer. As Dr. Kinane states, idiopathic pulmonary hemosiderosis is likely to be a heterogeneous condition, and an immunologic disorder may ultimately develop from it. It would therefore be interesting to assess the patient's HLA status (the presence or absence of the B51 allele) and perform a pathergy test to better investigate a possible association between Behçet's disease and idiopathic pulmonary hemosiderosis. To the Editor: The child with idiopathic pulmonary hemosiderosis described by Boyer et al. fortunately had a response to treatment with hydroxychloroquine and oral corticosteroids. However, Data are mean (±SD) values for two measurements. Oxidative stress increased after each of two episodes of intrapulmonary hemorrhage resulting in hospital admission (arrows) and returned to baseline levels within a week. The first episode of hemorrhage occurred 5 days before urine sampling; the second, 4 days before. At week 6, the level of urinary 8-oxo-7,8-dihydro-2́-deoxyguanosine was below the assay's limit of detection.
some children with idiopathic pulmonary hemosiderosis continue to have episodes of intrapulmonary hemorrhage, despite immunosuppressive therapy. In our unit, an 11-year-old girl with idiopathic pulmonary hemosiderosis had 11 episodes of intrapulmonary hemorrhage over an 18-month period, despite treatment with oral prednisolone (20 to 40 mg once a day), azathioprine (75 mg once a day), and hydroxychloroquine (100 mg twice a day). Since free iron from blood may increase lung-tissue injury mediated by free radicals, 1 we measured oxidative stress, using a urinary biomarker (8-oxo-7,8-dihydro-2'-deoxyguanosine) 2 over a 6-month period. We found increased levels of oxidative stress during two additional episodes of intrapulmonary hemorrhage (Fig. 1) . Treatment with the glutathione prodrug acetylcysteine 3 (300 mg twice a day) was then started, and 6 months later, the patient remains clinically well while receiving a reduced dose of oral prednisolone (10 mg per day on alternate days). We conclude that the therapeutic potential of antioxidant therapy in children with idiopathic pulmonary hemosiderosis merits further study. Jonathan Grigg, M.D.
